Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Bedossa

Showing results (241-250 of 267) with videos related to

Pageof 27
Sort By:
Scientific Reports|February 15, 2020
Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model of Non-Alcoholic Fatty Liver DiseaseVincenzo Musolino, Micaela Gliozzi, Federica Scarano, et al.
Histopathology|May 22, 2024
Severe acute liver disease in adults: Contemporary role of histopathologyAndrew D Clouston, Annette S H Gouw, Dina Tiniakos, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 21, 2018
Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM StudyMaud Lemoine, Lambert Assoumou, Stephane De Wit, et al.
The Lancet. Gastroenterology & Hepatology|August 9, 2020
A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation studyStephen A Harrison, Vlad Ratziu, Jérôme Boursier, et al.
The Lancet. Gastroenterology & Hepatology|February 7, 2020
FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation studyPhilip N Newsome, Magali Sasso, Jonathan J Deeks, et al.
Alimentary Pharmacology & Therapeutics|August 16, 2021
Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetesThierry Poynard, Valérie Paradis, Jimmy Mullaert, et al.
Journal of Hepatology|November 17, 2023
Adipose tissue macrophage dysfunction is associated with a breach of vascular integrity in NASHMarkus Boesch, Andreas Lindhorst, Rita Feio-Azevedo, et al.
JHEP Reports : Innovation in Hepatology|June 9, 2025
Altered liver sinusoidal endothelial cells in MASLD and their evolution following lanifibranor treatmentPierre-Emmanuel Rautou, Shivani Chotkoe, Louise Biquard, et al.
Journal of Hepatology|October 10, 2025
Consensus position statements for the standardized application of histological grading and staging systems in MASH clinical trialsCarolin Lackner, Annette S H Gouw, Venancio Avancini Ferreira Alves, et al.
The New England Journal of Medicine|October 20, 2021
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASHSven M Francque, Pierre Bedossa, Vlad Ratziu, et al.
Pageof 27

Showing results (241-250 of 267) with videos related to

Sort By:
Pageof 27
Scientific Reports|February 15, 2020
Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model of Non-Alcoholic Fatty Liver DiseaseVincenzo Musolino, Micaela Gliozzi, Federica Scarano, et al.
Histopathology|May 22, 2024
Severe acute liver disease in adults: Contemporary role of histopathologyAndrew D Clouston, Annette S H Gouw, Dina Tiniakos, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 21, 2018
Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM StudyMaud Lemoine, Lambert Assoumou, Stephane De Wit, et al.
The Lancet. Gastroenterology & Hepatology|August 9, 2020
A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation studyStephen A Harrison, Vlad Ratziu, Jérôme Boursier, et al.
The Lancet. Gastroenterology & Hepatology|February 7, 2020
FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation studyPhilip N Newsome, Magali Sasso, Jonathan J Deeks, et al.
Alimentary Pharmacology & Therapeutics|August 16, 2021
Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetesThierry Poynard, Valérie Paradis, Jimmy Mullaert, et al.
Journal of Hepatology|November 17, 2023
Adipose tissue macrophage dysfunction is associated with a breach of vascular integrity in NASHMarkus Boesch, Andreas Lindhorst, Rita Feio-Azevedo, et al.
JHEP Reports : Innovation in Hepatology|June 9, 2025
Altered liver sinusoidal endothelial cells in MASLD and their evolution following lanifibranor treatmentPierre-Emmanuel Rautou, Shivani Chotkoe, Louise Biquard, et al.
Journal of Hepatology|October 10, 2025
Consensus position statements for the standardized application of histological grading and staging systems in MASH clinical trialsCarolin Lackner, Annette S H Gouw, Venancio Avancini Ferreira Alves, et al.
The New England Journal of Medicine|October 20, 2021
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASHSven M Francque, Pierre Bedossa, Vlad Ratziu, et al.
Pageof 27